Avesthagen Begins Human Trials Of Diabetes 'Bioactives'

Add as a preferred source on Google

Hyderabad, Avesthagen Limited, a knowledge-based Systems Biology Company, today announced the commencement of Phase III human clinical trials for its recently launched 'Avestaa' brand of botanical 'bioactives'.

In a statement here, Company Founder, Chairperson and Managing Director Villoo Morawala Patell said Avesthagen Limited and Manipal AcuNova Limited, Bangalore, had a strategic agreement for conducting the Phase III human clinical studies for diabetes management for Avesthagen's branded 'bioactives' 'Teestar', 'Aspand' and 'Cincata.' These products were developed by the bio nutrition division of the company from different medicinal plants selected from its proprietary database - ADePt, and validated using MetaGrid, its patented comprehensive constituent profiling technology.

'Teestar' intervenes with carbohydrate metabolism and leads to significant reduction of blood glucose levels. 'Aspand' inhibits Dipeptidyl Peptidase IV and sensitises insulin while 'Cincata' inhibits a-glucosidase and synergises with insulin, thereby increasing its potency, she claimed.

During pre-clinical studies, all three 'bioactives' recorded a significant decrease in blood sugar levels in diabetic animal models and in the level of glycated haemoglobin HbA1c in comparison to the controls.

Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.